289 related articles for article (PubMed ID: 12271292)
1. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
Fisler RE; Liang MG; Fuhlbrigge RC; Yalcindag A; Sundel RP
J Am Acad Dermatol; 2002 Oct; 47(4):505-11. PubMed ID: 12271292
[TBL] [Abstract][Full Text] [Related]
2. Twelve years experience of juvenile dermatomyositis in North India.
Singh S; Bansal A
Rheumatol Int; 2006 Apr; 26(6):510-5. PubMed ID: 16163542
[TBL] [Abstract][Full Text] [Related]
3. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
Walling HW; Gerami P; Sontheimer RD
Paediatr Drugs; 2010; 12(1):23-34. PubMed ID: 20034339
[TBL] [Abstract][Full Text] [Related]
4. Juvenile dermatomyositis in Thai children: Retrospective review of 30 cases from a tertiary care center.
Nitiyarom R; Charuvanij S; Likasitwattanakul S; Thanoophunchai C; Wisuthsarewong W
Indian J Dermatol Venereol Leprol; 2022; 88(2):162-170. PubMed ID: 34491668
[TBL] [Abstract][Full Text] [Related]
5. Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis.
Wang A; Morgan GA; Paller AS; Pachman LM
J Am Acad Dermatol; 2021 Jun; 84(6):1610-1618. PubMed ID: 33359787
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis.
Tayfur AC; Topaloglu R; Gulhan B; Bilginer Y
Mod Rheumatol; 2015 Jul; 25(4):615-20. PubMed ID: 25800510
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.
Marco Puche A; Calvo Penades I; Lopez Montesinos B
Clin Exp Rheumatol; 2010; 28(1):135-40. PubMed ID: 20346254
[TBL] [Abstract][Full Text] [Related]
8. Juvenile dermatomyositis: a tertiary center experience.
Barut K; Aydin PO; Adrovic A; Sahin S; Kasapcopur O
Clin Rheumatol; 2017 Feb; 36(2):361-366. PubMed ID: 28058540
[TBL] [Abstract][Full Text] [Related]
9. The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients.
Giancane G; Lavarello C; Pistorio A; Oliveira SK; Zulian F; Cuttica R; Fischbach M; Magnusson B; Pastore S; Marini R; Martino S; Pagnier A; Soler C; Staņēvicha V; Ten Cate R; Uziel Y; Vojinovic J; Fueri E; Ravelli A; Martini A; Ruperto N;
Pediatr Rheumatol Online J; 2019 May; 17(1):24. PubMed ID: 31118099
[TBL] [Abstract][Full Text] [Related]
10. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.
Ambler GR; Chaitow J; Rogers M; McDonald DW; Ouvrier RA
J Rheumatol; 2005 Sep; 32(9):1837-9. PubMed ID: 16142885
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcomes with reduced steroid use in juvenile dermatomyositis.
Orandi AB; Fotis L; Lai J; Morris H; White AJ; French AR; Baszis KW
Pediatr Rheumatol Online J; 2021 Aug; 19(1):127. PubMed ID: 34404425
[TBL] [Abstract][Full Text] [Related]
12. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists.
Hinze CH; Speth F; Oommen PT; Haas JP
Pediatr Rheumatol Online J; 2018 Jun; 16(1):38. PubMed ID: 29925381
[TBL] [Abstract][Full Text] [Related]
13. Medications received by patients with juvenile dermatomyositis.
Kishi T; Bayat N; Ward MM; Huber AM; Wu L; Mamyrova G; Targoff IN; Warren-Hicks WJ; Miller FW; Rider LG;
Semin Arthritis Rheum; 2018 Dec; 48(3):513-522. PubMed ID: 29773230
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
Marhaug G; Shah V; Shroff R; Varsani H; Wedderburn LR; Pilkington CA; Brogan PA
Rheumatology (Oxford); 2008 Jul; 47(7):1031-7. PubMed ID: 18448482
[TBL] [Abstract][Full Text] [Related]
15. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases.
Sato JO; Sallum AM; Ferriani VP; Marini R; Sacchetti SB; Okuda EM; Carvalho JF; Pereira RM; Len CA; Terreri MT; Lotufo SA; Romanelli PR; Ramos VC; Hilario MO; Silva CA; Corrente JE; Saad-Magalhães C;
Clin Exp Rheumatol; 2009; 27(6):1031-8. PubMed ID: 20149327
[TBL] [Abstract][Full Text] [Related]
16. Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Lanis A; Volochayev R; Kleiner DE; Vittal A; Heller T; Rider LG; Shenoi S
Pediatr Rheumatol Online J; 2022 Apr; 20(1):30. PubMed ID: 35443665
[TBL] [Abstract][Full Text] [Related]
17. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment.
Kim S; El-Hallak M; Dedeoglu F; Zurakowski D; Fuhlbrigge RC; Sundel RP
Arthritis Rheum; 2009 Jun; 60(6):1825-1830. PubMed ID: 19479872
[TBL] [Abstract][Full Text] [Related]
18. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
Sanner H; Sjaastad I; Flatø B
Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the clinical characteristics and therapeutic effect of refractory juvenile dermatomyositis to tofacitinib].
Zhou QF; Luo Y; He TY; Ling JY; Xu YB; Yang J; Xia Y
Zhonghua Er Ke Za Zhi; 2023 Jun; 61(6):538-542. PubMed ID: 37312466
[No Abstract] [Full Text] [Related]
20. Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil.
Çakan M; Karadağ ŞG; Ayaz NA
Turk J Pediatr; 2019; 61(5):771-775. PubMed ID: 32105011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
